# Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

> **NCT05841160** · PHASE1 · COMPLETED · sponsor: **Emalex Biosciences Inc.** · enrollment: 29 (actual)

## Conditions studied

- QT/QTc

## Interventions

- **DRUG:** Ecopipam Hydrochloride
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05841160
- **Lead sponsor:** Emalex Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-15
- **Primary completion:** 2023-05-07
- **Final completion:** 2023-05-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-06-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05841160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05841160, "Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05841160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*